Core Viewpoint - The A-share market is experiencing a positive trend in Q1 2026 earnings forecasts, with a significant majority of companies reporting expected profit increases, indicating overall market optimism [1]. Group 1: Earnings Forecasts - As of March 29, 2026, 18 companies have disclosed their Q1 earnings forecasts, with 88.89% expecting profit increases, including 10 companies forecasting substantial growth, 5 slight increases, and 1 company turning a loss into profit [1]. - The sectors showing the highest growth are machinery, pharmaceuticals, and basic chemicals, driven by both volume and price increases [1]. Group 2: Notable Companies - Oukeyi is expected to report a net profit of 180 million to 220 million yuan, representing a year-on-year increase of 2248.9% to 2770.9%, primarily due to the rise in hard alloy tool prices and a low base effect from the previous year [1]. - Fuxiang Pharmaceutical forecasts a net profit of 52 million to 75 million yuan, with a year-on-year growth of 2222.67% to 3250.01%, benefiting from the booming demand in the new energy sector [2]. - Kuncai Technology is projected to achieve a net profit of 60 million to 80 million yuan, marking a year-on-year increase of 151.56% to 235.41%, driven by the recovery in titanium dioxide prices [2]. Group 3: Growth Drivers - Wanbangde is expected to report a net profit of 165 million yuan, reflecting a year-on-year increase of 985.4%, attributed to its strategic shift from generic to innovative drugs and increased R&D investment [3]. - Gude Electric Materials anticipates a revenue growth of 41.41% to 53.89%, with a net profit forecast of 48 million to 51 million yuan, driven by successful expansion into copper-aluminum composite materials [3]. Group 4: Other Notable Performances - Aolaide expects a net profit of 70 million to 85 million yuan, with a year-on-year growth of 175.2% to 234.17%, due to its competitive advantage in evaporator equipment [4]. - Tianshan Aluminum is projected to achieve a net profit of 2.2 billion yuan, a year-on-year increase of 107.92%, benefiting from the capacity release of its green low-carbon aluminum project [4].

Core Viewpoint - Tianshan Aluminum is expected to achieve a net profit of 2.2 billion yuan in Q1 2026, representing a year-on-year increase of 107.92% [1] Group 1: General Performance Trends - The performance increase of Tianshan Aluminum reflects a broader trend among A-share companies, with many forecasting significant profit growth for Q1 2026 [2][3] - As of the report, 17 A-share companies have disclosed their Q1 2026 performance forecasts, with several, including Okoyi and Fuxiang Pharmaceutical, expecting net profit growth exceeding 100% [4] Group 2: Specific Company Forecasts - Okoyi anticipates a net profit of 180 million to 220 million yuan for Q1 2026, with a year-on-year growth rate of 2248.9% to 2770.9% [4] - Fuxiang Pharmaceutical expects a net profit of 52 million to 75 million yuan, marking a growth of 2222.67% to 3250.01% compared to the previous year [4] - Wanbang expects a net profit of 165 million yuan, reflecting a growth of 985.40% year-on-year [5] - Fuliwang forecasts a net profit of 40 million to 50 million yuan, with a growth rate of 183.84% to 254.81% [5] Group 3: Reasons for Performance Increases - The reasons for the expected profit increases vary by company, including improved industry conditions, new growth points, and low comparison bases from the previous year [6] - Okoyi cites rising raw material costs and increased production capacity as key factors for its growth [7] - Fuxiang Pharmaceutical benefits from the growing demand in the new energy sector, particularly in lithium battery materials [7] - Wanbang's transition from generic to innovative drugs has started to yield positive results, contributing to its performance [7] - Fuliwang attributes its growth to increased revenue from its 3C consumer electronics business and improved operational efficiency [8] - Tianshan Aluminum reports a 10% increase in aluminum production and a 17% rise in sales prices, alongside effective cost control [8]

| 基本数据 | 2026-03-26 | | --- | --- | | 当前股价（元） | 18.44 | | 总市值（亿元） | 99 | | 总股本（百万股） | 539 | | 流通股本（百万股） | 441 | | 52 周价格范围（元） | 6.98-21.15 | | 日均成交额（百万元） | 394.34 | 市场表现 -50 0 50 100 150 200 (%) 富祥药业 沪深300 相关研究 —富祥药业（300497.SZ）公司事件点评报告 2026 年 03 月 27 日 新业务迎来收获阶段，业绩大幅扭亏 买入(首次) 事件 | | | 富祥药业发布公告：预计 2025 年度实现营业收入 11.85 亿 元，归属于上市公司股东的净利润为-5306.77 万元。 富祥药业发布公告：预计 2026 年度 Q1 实现归属于上市公司股 东的净利润为 5200 万元至 7500 万元。 投资要点 ▌ 反内卷推动价格上行，新能源业务扭亏为盈 公司新能源业务（电解液添加剂 VC/FEC）建成投产于 2022 年，多年的投入和行业低价竞争，已经持续 3 年亏损，2022 年至 2024 年该业务的 ...

2026 年 03 月 27 日 新业务迎来收获阶段，业绩大幅扭亏 买入(首次) 事件 | | | | 基本数据 | 2026-03-26 | | --- | --- | | 当前股价（元） | 18.44 | | 总市值（亿元） | 99 | | 总股本（百万股） | 539 | | 流通股本（百万股） | 441 | | 52 周价格范围（元） | 6.98-21.15 | | 日均成交额（百万元） | 394.34 | 市场表现 -50 0 50 100 150 200 (%) 富祥药业 沪深300 相关研究 —富祥药业（300497.SZ）公司事件点评报告 富祥药业发布公告：预计 2025 年度实现营业收入 11.85 亿 元，归属于上市公司股东的净利润为-5306.77 万元。 富祥药业发布公告：预计 2026 年度 Q1 实现归属于上市公司股 东的净利润为 5200 万元至 7500 万元。 投资要点 ▌ 反内卷推动价格上行，新能源业务扭亏为盈 公司新能源业务（电解液添加剂 VC/FEC）建成投产于 2022 年，多年的投入和行业低价竞争，已经持续 3 年亏损，2022 年至 2024 年该业务的 ...

近日，江西富祥药业股份有限公司（以下简称"公司"）及子公司景德镇富祥生 命科技有限公司获得1件由美国专利商标局、1件由韩国知识产权局颁发的发明专利证 书，具体情况如下： 一、发明专利证书基本情况 （一）发明名称：一种三氟甲基芳香化合物的制备方法 美国专利号：US 12,404,231 B2 美国申请号：18/857,747 证券代码：300497 证券简称：富祥药业 公告编号：2026-027 江西富祥药业股份有限公司 关于取得美国、韩国发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 韩国专利号：10-2887547 韩国申请号：10-2024-7031938 授权日：2025年11月13日 专利权人：景德镇富祥生命科技有限公司；江西富祥药业股份有限公司 发明人：李惠跃、陈应惠、晏金华、文海红、姚建、陶伟锋 地址：江西省景德镇高新区 (景德镇电厂南侧)，333000；江西省景德镇市昌江区 鱼丽工业区2号（鱼山与丽阳交界处），333000 二、取得发明专利证书对公司的影响 授权日：2025年9月2日 专利权人：景德镇富祥生命科技有限公司 发明 ...

专利权人：江西富祥生物科技有限公司 证券代码：300497 证券简称：富祥药业 公告编号：2026-026 江西富祥药业股份有限公司 关于取得美国发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，江西富祥药业股份有限公司（以下简称"公司"）子公司江西富祥生物科 技有限公司获得1项由美国专利商标局颁发的发明专利证书，具体情况如下： 一、发明专利证书基本情况 （一）发明名称：短柄镰刀菌在生产菌丝体蛋白中的应用 美国专利号：US 12,529,027 B2 申请号：18/850,239 授权日：2026年1月20日 董事会 发明人：包建华、屠亚东、李佳璐、李惠跃、陈应惠 地址：江西省景德镇市昌江区发电厂南侧，333000 二、取得发明专利证书对公司的影响 近年来，公司基于医药行业多年来积累的优势资源，拓展了合成生物学微生物蛋 白业务，已成为国内首家实现丝状真菌蛋白千吨级产业化的企业。公司具有完全自主 知识产权的新型生产菌株——短柄镰刀菌，经中国轻工业联合会鉴定委员会鉴定，"短 柄镰刀菌发酵生产微生物蛋白关键技术及工业化应用"项目整体技术达到国 ...

Market Overview - A-shares collectively rose on Wednesday, with the Shanghai Composite Index up 1.30% to 3,931.84 points, and nearly 4,900 stocks increased in value[15] - U.S. stocks rebounded significantly, with the Dow Jones up 0.66% to 46,428 points, driven by hopes for diplomatic resolutions in the U.S.-Iran conflict[9] - European markets also saw gains, with the Euro Stoxx 600 rising 1.4%, reflecting improved market sentiment[9] Commodity and Currency Trends - International oil prices fell, with WTI crude down 2.20% to $90.32 per barrel, easing inflation concerns and cooling interest rate hike expectations[28] - Gold prices increased by 3.41% to $4,552.3 per ounce, benefiting from the drop in oil prices[28] - The U.S. dollar index rose 0.2% to 99.6, marking its second consecutive day of gains[28] Fixed Income Market - U.S. Treasury yields declined, with the 10-year yield down 2.8 basis points to 4.33%, as liquidity improved following the drop in oil prices[31] - The Chinese IG spread narrowed by 3-10 basis points, indicating a strengthening sentiment in the Asian bond market[31] Key Economic Indicators - The Chinese government set a GDP growth target range of 4.5%-5.0% for 2026, emphasizing the need for labor productivity to exceed GDP growth[6] - Urbanization rate target was raised to 71.0%, focusing on quality improvements to unleash domestic demand potential[6] Individual Stock Highlights - Pinduoduo reported a 12% year-on-year revenue increase to 124 billion RMB, exceeding expectations, with GMV projected to grow 70% to $30 billion[9] - Meituan's stock surged nearly 14% following regulatory support for ending the "takeout war" in the internet sector[11]

证券代码：300497 证券简称：富祥药业 公告编号：2026-025 江西富祥药业股份有限公司 2026年第一季度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2026 年 1 月 1 日至 2026 年 3 月 31 日 四、其他相关说明 1、本次业绩预告是公司财务部门初步测算的结果，未经审计机构审计。 2、2026 年第一季度的具体财务数据将在本公司 2026 年第一季度报告中予以详细 披露。敬请广大投资者谨慎决策，注意投资风险。 2、预计的业绩：预计净利润为正值且属于同向上升 50%以上情形 3、业绩预告情况表： | 项目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | 盈利：5200 | 万元-7500 | 万元 | 盈利：223.88 | 万元 | | | 比上年同期增长：2222.67%-3250.01% | | | | | | 扣除非经常性损益 后的净利润 | 盈利：5000 | 万元 ...

证券代码：300497 证券简称：富祥药业 公告编号：2026-024 江西富祥药业股份有限公司 2025年度业绩快报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示：本公告所载 2025 年度的财务数据仅为初步核算数据，未经会计师事 务所审计，与年度报告中披露的最终数据可能存在差异，请投资者注意投资风险。 一、本期业绩预计情况 （二）报告期内，主要指标变动原因 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动 | 变动主要原因 | | --- | --- | --- | --- | --- | | | | | 幅度 | | | 营业利润 | -6,154.52 | -28,707.17 | 78.56% | 公司三大业务协同发 | | | | | | 展，新能源电解液添加 | | 利润总额 | -6,314.02 | -28,856.38 | 78.12% | 剂产品价格上涨，带动 | | 归属于上市公司股东的净利 | -5,306.77 | -27,210.06 | 80.50% | 业务盈利改善以及医 | | 润 | | | | ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can drive industrial structure optimization and economic model transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the development status and trends of biomanufacturing, analyzing the industry chain and key application directions [1]. - It compares the competitive landscape of biomanufacturing between China and the United States, identifying key differences and opportunities [7]. - Future development trends in biomanufacturing are discussed, indicating potential areas for growth and innovation [7]. Group 2: Policy Landscape - The report outlines major domestic and international policies affecting the biomanufacturing sector for 2024-2025, providing insights into regulatory environments [7]. - It details foreign policies that influence the global biomanufacturing industry, as well as domestic policies that shape the Chinese market [7]. Group 3: Industry Mapping and Key Players - The white paper identifies the "10 Leading Enterprises" in China's biomanufacturing industry, showcasing significant players and their contributions [7]. - It lists 15 publicly listed companies involved in synthetic biology, summarizing their strategic directions and investments in the field [7]. - The report highlights 20 popular products in the biomanufacturing space, linking them to corresponding companies [7]. Group 4: Challenges and Recommendations - The document discusses the challenges faced by China's biomanufacturing industry, including technological, regulatory, and market-related issues [7]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [7].